Deficiency of Peptidylglycine-alpha-amidating Monooxygenase, a Cause of Sarcopenic Diabetes Mellitus
PAM-AMA genetic deficiency results in a prediabetic sarcopenic phenotype. Early identification of PAM LoF carriers would allow targeted exercise interventions and calls for novel therapies that restore enzymatic activity.
Authors
- Marcus Herbert Jones (ORCID: https://orcid.org/0000-0002-8263-1265)
- Alice Giontella (ORCID: https://orcid.org/0000-0001-7242-437X)
- Yulia Ilina (ORCID: https://orcid.org/0000-0002-9045-9055)
- John D. Overton (ORCID: https://orcid.org/0000-0001-7650-8634)
- Aris Baras (ORCID: https://orcid.org/0000-0002-6830-3396)
- Andreas Bergmann (ORCID: https://orcid.org/0000-0001-8006-4888)
- Luca A. Lotta (ORCID: https://orcid.org/0000-0002-2619-5956)
- Cristiano Fava (ORCID: https://orcid.org/0000-0002-8910-7378)
- Kevin Bronton (ORCID: https://orcid.org/0000-0001-5876-2655)
- Mikael Åkerlund
- Olle Melander (ORCID: https://orcid.org/0000-0002-2581-484X)
- Paul Kaufmann (ORCID: https://orcid.org/0000-0002-5631-9403)
Institutions
- University of Verona (IT)
- Malmö University (SE)
- Regeneron (United States) (US)
- Lund University (SE)
- Immundiagnostik (Germany) (DE)
- Skåne University Hospital (SE)
- InfectoGnostics Research Campus Jena (DE)
Publication Details
- Journal
- The Journal of Clinical Endocrinology & Metabolism
- Published
- 2024-08-13
- DOI
- https://doi.org/10.1210/clinem/dgae510
- Citations
- 9
- Primary Topic
- Nutrition and Health in Aging
- Type
- article
- Field-Weighted Citation Impact
- 2.94
Funders
- Stiftelsen för Strategisk Forskning
- Vetenskapsrådet
- Novo Nordisk Fonden